Text and Data Mining valid from 2015-10-23
First Online: 23 October 2015
: The following authors declare competing interests: D.D.B. has received research grant funding from Astra Zeneca, Pfizer and Roche. M.A.B. declares participation in ad-hoc advisory boards regarding investigational (non-marketed) agents for development of clinical trials in ovarian cancer, including AbbVie, AstraZeneca, Novartis, Sanofi-Aventis, Clovis, Daiichi-Sankyo, Cerulean, Emdocyte, Immunogen, Oxigene, Genentech-Roche and Boehringer Ingelheim. He declares financial compensation and travel support for these meetings. He has participated in Independent Data Monitoring Committees (IDMC) for Phase III trials in ovarian cancer for Genentech-Roche and Boehringer Ingelheim, with financial compensation for time and travel. J.D.B. is cofounder and own shares in Inivata Ltd. R.C.B. has royalties from Fujirebio Diagnostics. G.C. has undertaken consultancies for Roche, Sanofi and Pierre-Fabre, and has grants or support for research from Boehringer Ingelheim. R.D. is on the scientific advisory board of Siamab Therapeutics. C.G's employer (Edinburgh University) has received payments for his attendance at advisory boards from Roche, AstraZeneca and Nucana, for his lectures from Roche and AstraZeneca, and for clinical research from AstraZeneca, Aprea and GlaxoSmithKline. He is named as an inventor on issued patents and patent applications regarding the Almac AADX assay. J.G. is cofounder and shareholder of HalioDx Biotech company. D.G.H. is founder, shareholder and Chief Medical Officer of Contextual Genomics. B.Y.K. has grants or support for research from AstraZeneca, Tesaro, Dana-Farber Cancer Center/NCI, Amgen and Cancer International Research Group, and is co-inventor of 'Molecular Signatures of Ovarian Cancer', patent pending. D.A.L. declares speaking honoraria from Roche Products, has a patent application on Detection of Ovarian Cancer and stock options in Critical Outcomes Technologies I.A.M. is on advisory boards for Clovis Oncology, Astra Zeneca and Roche. U.M. owns stock in Abcodia that has an interest in early detection of ovarian cancer. D.J.P. has obtained consulting fees from Lion Biotherapeutics, research funding through an alliance between The University of Pennsylvania and Novartis, and patents on the application of chimeric antigen receptors in oncology. C.L.S. has had honoraria, travel and accommodation expenses from Roche, Astra Zeneca, Clovis Oncology and given expert testimony for Astra Zeneca and Speakers' Bureau Prime Oncology. All other authors declare no competing interests.